【摘要】 目的回顾性分析EGFR-TKIs治疗EGFR敏感突变的晚期非小细胞肺癌的临床资料和疗效、生存情况,探索影响疗效和预后的相关因素。方法收集65例福建省肿瘤医院2012年2月至2015年2月诊治的口服EGFR-TKI治疗的EGFR敏感突变的晚期(Ⅳ期)非小细胞肺癌患者的临床资料,分析其与EGFR-TKI的疗效关系。结果 65例患者中,ORR 69.2%,DCR 96.9%。不同临床特征的各亚组间ORR率及DCR率差异无统计学意义。全组患者的中位PFS和中位OS分别为11.0月、28.0月。多因素回归分析显示:ECOG评分、基因突变类型(19del/L858R)为PFS的影响因素,ECOG评分为影响OS的独立因素。结论(1)EGFR-TKI治疗EGFR敏感突变的不同临床特征的患者均可获益,近期有效率及疾病控制率没有差别;(2)ECOG评分是影响PFS及OS的重要影响因素;(3)不同突变类型影响PFS(TKI)时间,19DEL突变者PFS优于L858R突变者。更多还原

【Abstract】 Objective The aim of the retrospective study was to investigate the efficacy of EGFR-TKIs for stage IV non-small cell lung cancer patients with sensitive EGFR mutations,and to observe the influencing factors.Methods We retrospectively analyzed the clinical datas of 65 patients with stage IV NSCLC harboring EGFR mutation who were treated with EGFR-TKIs from February 2012 to February 2015 in Fujian Provincial Tumor Hospital to investigate the efficacy,and survival was followed up.Results Among the 65 patients,the response rate was 69.2% and the disease control rate was 96.9%.There were no significant differences were found about ORR and DCR in patients with different clinical characteristics.The median progression-free survival(m PFS) and median survival(m OS) was 11.0 months and 28.0 months,respectively.Cox regression model indicated that PFS was significantly related to ECOG score and EGFR mutation statuses(19 del/L858R).Multivariate analysis shows and only ECOG score was independent prognostic factor of the OS.Conclusions EGFR-TKI treatment is benefit to patients with different clinical features of EGFR Mutation-positive NSCLC,ORR and DCR does not differ.ECOG score is the most important influencing factor for PFS and OS time of patients.EGFR mutation statuses affect the PFS,which is more efficient in patients with EGFR exon 19 deletion than those with EGFR L858 R mutation.更多还原